The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta.


Journal

PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 1 5 2019
medline: 1 5 2019
entrez: 1 5 2019
Statut: ppublish

Résumé

Our objective was to describe the costs of industry-sponsored clinical trials for medical devices in Northern Alberta, Canada. We used centralized data to identify all industry-sponsored medical device clinical trials initiated in Northern Alberta from 2012 to 2016. For each arm of each trial, we calculated the price of devices provided by the sponsor and the cost of clinical and administrative services that were incurred to clinically operationalize the treatment. Our sample consisted of 18 device trials initiated between January 2012 and January 2016. The overall cost (Canadian dollars [$Can], year 2018 values) per enrolee was $Can18,243 for the experimental arm and $Can13,827 for the control arm. Devices were the highest cost component, at $Can13,446 per enrollee in the experimental arm. Clinical costs in the control arms were higher on average ($Can7202 vs. 2504) than those in the experimental arms. Data from industry-sponsored clinical trials can provide important information on the full costs of device-related interventions. As device costs rise, and as policy makers require more evidence on device-related treatments, the cost of medical device-driven interventions should be documented along with their effectiveness.

Identifiants

pubmed: 31037645
doi: 10.1007/s41669-019-0137-0
pii: 10.1007/s41669-019-0137-0
pmc: PMC6861404
doi:

Types de publication

Journal Article

Langues

eng

Pagination

591-597

Références

J Pharm Pharm Sci. 2017;20(1):407-414
pubmed: 29197429
Appl Health Econ Health Policy. 2014 Dec;12(6):611-22
pubmed: 25086585
Heart. 2016 Nov 1;102(21):1742-1749
pubmed: 27411837
Pharmacoeconomics. 2003;21(16):1171-83
pubmed: 14594438
J Am Coll Cardiol. 2012 Oct 2;60(14):1271-7
pubmed: 22981547
Pharmacoecon Open. 2017 Mar;1(1):65-68
pubmed: 29442299
Circulation. 2010 Dec 14;122(24):2545-50
pubmed: 21126973
Contemp Clin Trials. 2011 Jul;32(4):485-91
pubmed: 21530679
Value Health. 2016 Sep - Oct;19(6):720-726
pubmed: 27712696
Health Aff (Millwood). 2018 Oct;37(10):1570-1577
pubmed: 30273022
Contemp Clin Trials. 2010 Nov;31(6):524-9
pubmed: 20840876
Am J Cardiol. 2011 Aug 15;108(4):572-4
pubmed: 21624555

Auteurs

Ilke Akpinar (I)

School of Public Health, University of Alberta, 3-267 Edmonton Clinic Health Academy, 11405-87 Ave, Edmonton, AB, T6G 1C9, Canada. ilke@ualberta.ca.

Arto Ohinmaa (A)

School of Public Health, University of Alberta, 3-267 Edmonton Clinic Health Academy, 11405-87 Ave, Edmonton, AB, T6G 1C9, Canada.

Lars Thording (L)

Innovative Health, Scottsdale, AZ, USA.

Dat T Tran (DT)

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.

Richard N Fedorak (RN)

Department of Medicine, University of Alberta, Edmonton, AB, Canada.

Lawrence Richer (L)

Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.

Philip Jacobs (P)

Department of Medicine, University of Alberta, Edmonton, AB, Canada.

Classifications MeSH